GSE182680 GSE182683 dexamethasone 0 v 9 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE182680_GSE182683_dexamethasone_0_v_9_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE182680_GSE182683_dexamethasone_0_v_9_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE182680_GSE182683_dexamethasone_0_v_9_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE182680_GSE182683_dexamethasone_0_v_9_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

MSL complex subunit 3B

Gene

long intergenic non-protein coding RNA 665

Gene

long intergenic non-protein coding RNA 2910

Gene

TALAM1 transcript, MALAT1 antisense RNA

Gene

long intergenic non-protein coding RNA 649

Gene

TPTE pseudogene 1

Gene

MT-ND2 pseudogene 28

Gene

SBF2 antisense RNA 1

Gene

prothymosin alpha pseudogene 5

Gene

TCF12 divergent transcript

  • Gene

    MSL complex subunit 3B


  • Gene

    long intergenic non-protein coding RNA 665


  • Gene

    long intergenic non-protein coding RNA 2910


  • Gene

    TALAM1 transcript, MALAT1 antisense RNA


  • Gene

    long intergenic non-protein coding RNA 649


  • Gene

    TPTE pseudogene 1


  • Gene

    MT-ND2 pseudogene 28


  • Gene

    SBF2 antisense RNA 1


  • Gene

    prothymosin alpha pseudogene 5


  • Gene

    TCF12 divergent transcript

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.